可溶性IgM型CTLA4分子の作製

概要

論文の詳細を見る
Allograft rejection is primarily dependent on recognition and activation of alloreactive T cells, which require both T cell receptor engagement by antigen and costimulatory signals delivered by T cell surface molecules such as CD28. CTLA4IgG, a soluble recombinant fusion protein of extracel-lular portion of CTLA4 and Fc portion of human IgG, has previously been shown to block the CD28-mediated costimulatory signals and inhibit immune responses in vitro and in vivo. In this report, we produced a novel soluble chimeric molecule of murine CTLA4 and human IgM Fcμ (CTLA4IgM) and analyzed its binding activity to B7-1 molecules. CTLA4IgM specifically binds to B7-1+ CHO cells.
札幌医科大学の論文
1994-12-01